The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Medication User Questio

PLCO试验是一项大规模的随机试验，旨在研究前列腺癌、肺癌、结肠癌和卵巢癌的筛选试验是否会降低这些癌症的死亡率。1992年至2001年期间，约有155 000名年龄在55至74岁之间的妇女和男子参加了PLCO。参与者被随机分为两组，干预组参与者接受一系列六次年度检查，以筛查前列腺癌，肺癌，结直肠癌和卵巢癌，而对照组参与者接受健康提供者的常规医疗保健。参与者在基线时完成了一份风险因素问卷，并在2006年完成了一份补充问卷。另一份问卷（医疗使用问卷）旨在收集有关基本生活方式因素和药物使用的信息，于2013年上半年邮寄给PLCO参与者。大约56 000名参与者填写并交回了问卷。调查表的设计允许使用电子扫描方法和字符识别软件输入数据。参与者的答复已经计算机化，目前正在PLCO中央数据收集中心进行数据输入质量控制检查

The PLCO Trial was designed as a large-scale randomized trial to investigate whether selected screening tests for cancers of the prostate, lung, colon, and ovaries lead to a reduction in mortality from these cancers. Approximately 155,000 women and men aged 55 to74 were enrolled in PLCO between 1992 and 2001. Participants were randomized into two arms, with intervention-arm participants receiving a series of six annual examinations to screen for prostate cancer, lung cancer, colorectal cancer, and ovarian cancer, and comparison-arm participants receiving routine health care from their health providers. Participants completed a risk factor questionnaire at baseline and a supplemental questionnaire in 2006. Another questionnaire (the Medical Use Questionnaire), designed to collect information on basic lifestyle factors and medication use, was mailed to PLCO participants in the first half of 2013. Questionnaires were completed and returned by approximately 56,000 participants. The questionnaires were designed to allow data entry using electronic scanning methods and character recognition software. The participant responses have been computerized and are currently undergoing data entry quality control checks at the PLCO Central Data Collection Center